Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Calidi Biotherapeutics, Inc. Common Stock (NY:CLDI)

0.4251 -0.0149 (-3.39%)
Streaming Delayed Price Updated: 10:03 AM EDT, Apr 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Calidi Biotherapeutics, Inc. Common Stock

< Previous 1 2 3 Next >
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar Highlighting Cancer Immunotherapy Pipeline
Via Investor Brand Network
Portuguese Researchers Make Progress in Developing Immunotherapy Targeting Colorectal Cancer
Via Investor Brand Network
Portuguese Researchers Make Progress in Developing Immunotherapy Targeting Colorectal Cancer
Via Investor Brand Network
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Clearance to Begin Trials for CLD-201 in Solid Tumors
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Cancer Platforms, Reports Narrowed Loss for Q4 2024
Via Investor Brand Network
Study Explains Why Melanoma, Other Cancers Evade and Resist Immunotherapy
Via Investor Brand Network
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $3.9 Million Offering to Advance Immunotherapy Programs
Via Investor Brand Network
Natural Killer Cells That are Genetically Modified Show Potential in Cancer Immunotherapy
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces $3.9 Million Registered Direct Offering and Private Placement
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Encouraging Progress in Brain Cancer Trial with City of Hope
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments
Via Investor Brand Network
New Study Shows ‘Viral Mimicry’ Could Transform Glioblastoma Treatment
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) Novel Therapies Show Promise Against Aggressive Cancers
Via Investor Brand Network
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Promising Preclinical Results for RTNova Virotherapy Platform
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Stands at the Forefront of Integrating New Oncology Therapies
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Pioneers Systemic Virotherapy with RTNova Platform
Via Investor Brand Network
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) and OS Therapies (NYSE American: OSTX) to Appear on RedChip’s Bloomberg TV Show
Via Investor Brand Network
Exposures Product Safety
Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Drives Growth with Strengthened Financial Position and Cutting-Edge Research
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Sees Growth, Potential in Oncology Drug Development, a Critical Frontier in Cancer Treatment
Via Investor Brand Network
Topics Death
Exposures Death
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Launches “CLD-101” Trial for High-Grade Glioma at Northwestern
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focuses Innovation on Hard-to-Treat Tumors
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Focused on Advancing Stem Cell-Based Research Amid Rising Cancer Concerns
Via Investor Brand Network
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar on Feb. 5
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Ends SEPA Agreement Following Successful Fundraising
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present Breakthrough Virotherapy Platform at AACR 2025
Via Investor Brand Network
BioMedNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $4.25 Million Public Offering
Via Investor Brand Network
Topics Regulatory Compliance
Exposures Legal Regulatory
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces Public Offering of Common Stock and Warrants
Via Investor Brand Network
Topics Regulatory Compliance
Exposures Legal Regulatory
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) at the Forefront of Cancer Treatment Innovation
Via Investor Brand Network
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.